Patents Assigned to Centro de Inmunologia Molecular
-
Patent number: 11926654Abstract: The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.Type: GrantFiled: March 5, 2019Date of Patent: March 12, 2024Assignee: CENTRO DE INMUNOLOGIA MOLECULARInventors: Tays Hernández García, Maura Lisett Rábade Chediak, Kalet León Monzón, Circe Mesa Pardillo, Luis Enrique Fernández Molina, Giselle Hevia Hernández
-
Patent number: 11806396Abstract: This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) of Neisseria meningitidis in solutions containing fully synthetic variants of the GM3 ganglioside.Type: GrantFiled: October 24, 2018Date of Patent: November 7, 2023Assignee: Centro de Inmunología MolecularInventors: Luis Enrique Fernández Molina, Belinda Sánchez Ramírez, Audry Fernández Gómez, Gretchen Bergado Báez, Circe Mesa Pardillo, Lisset Chao García, Narjara González Suárez, Dayana Pérez Martínez, Diana Rosa Hernández Fernández, Mabel Cruz Rodríguez, Ángel Alexis Manso Vargas, Vicente Guillermo Verez Bencomo, Blanca Idelmis Tolón Murguía, Miguel Antonio López López, Jesús Arturo Junco Barranco
-
Patent number: 11766462Abstract: The present invention describes a pharmaceutical composition whose active ingredient includes conjugates of membrane vesicles of Neisseria meningitidis and the GM3 ganglioside in a conjugation ratio in excess of proteins, has particular characteristics of size, surface charge and a morphology associated with nano-particulate systems that give it advantageous properties as an immunomodulator, because it induces a convenient and significant reduction of myeloid-derived suppressor cells that has an impact on the response of lymphocytes and on the survival of patients with tumors. The invention further discloses the use of the pharmaceutical composition disclosed in the treatment of cancer, particularly those cancers where the myeloid-derived suppressor cells (MDSCs) are high; as well as a method of treatment with said composition in cancer patients and a method to select those who will receive said treatment.Type: GrantFiled: December 17, 2018Date of Patent: September 26, 2023Assignee: Centro de Inmunología MolecularInventors: Circe Mesa Pardillo, Liliana Oliver Ríos, Rydell Alvarez Arzola, Vladimir Peña Sánchez, Luis Enrique Fernández Molina, Anet Valdés Zayas, Maura Lisett Rábade Chediak, Lena Aguiar García, Lourdes Hernández de La Rosa, Audry Fernández Gómez, Leslie Pérez Ruíz, Camilo Rodríguez Rodríguez, Elias Antonio Gracia Medina, María Caridad Rubio Hernández, Orlando Valdés Guerrero, Idelmis Curbelo Haredia
-
Publication number: 20220344006Abstract: A computer based biological sequence analysis method provides, after a training phase adopting data from screening experiments, either an evaluation of an input sequence expressing the performance with reference to the chemical-physical feature object of the screening experiment, or at least an optimized output sequence. The method provides the use of a set or library of sequences derived from DMS experiments and SELEX for the generation of a second set of high efficiency biological sequences, whereby high efficiency means, for example, high catalysis capacity, high fitness, high ability to bind to a specific target, high fluorescence activity and, in general, a high performance with reference to the chemical-physical properties of a molecule which are defined at the start and can be selected through experiments.Type: ApplicationFiled: June 19, 2020Publication date: October 27, 2022Applicants: POLITECNICO DI TORINO, CENTRO DE INMUNOLOGÍA MOLECULARInventors: Guido UGUZZONI, Andrea PAGNANI, Jorge FERNANDEZ DE COSSIO DIA
-
Publication number: 20210238246Abstract: The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.Type: ApplicationFiled: March 5, 2019Publication date: August 5, 2021Applicant: Centro de Inmunologia MolecularInventors: Tays HERNÁNDEZ GARCíA, Maura Lisett RÁBADE CHEDIAK, Kalet LEÓN MONZÓN, Circe MESA PARDILLO, Luis Enrique FERNÁNDEZ MOLINA, Giselle HEVIA HERNÁNDEZ
-
Patent number: 10669346Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: May 9, 2018Date of Patent: June 2, 2020Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULARInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 10457747Abstract: Provided is a method for obtaining high-yield, stable expression cell clones from myeloma cell lines in a protein-free culture medium. The method is used for industrial production of a recombinant antibody, and includes three stage: (1) adapting to a protein-free culture medium, statically culturing cells at a low density, and gradually reducing a fat-rich supplement to a chemical culture medium; (2) adapting to a protein-free culture medium; culturing cells at a high density, and using a perfusion fermentation system in a laboratory scale; and (3) screening high-yield, stable expression cell clones from the cells after fermentation ends. The cell clone may be used to produce a humanized anti-NeuGcGM3 14F7 recombinant antibody.Type: GrantFiled: March 11, 2016Date of Patent: October 29, 2019Assignees: BIOTECH PHARMACEUTICAL CO. LTD., CENTRO DE INMUNOLOGIA MOLECULARInventors: MeyLen Chea, Julio Palacios, Miguel Arias, Loany Calvo, Tamara González, Rolando Pérez, Zhi Bai, Yuemao Liu, Kaiheng Xiao, Xiao Chen, Zhenhua He, Yangliu Cai, Zhenhua Yang, Xianhong Bai
-
Patent number: 9701730Abstract: The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGF? molecule whose primary sequence has a high homology with the sequence of human TGF?. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (T?RII and T?RIII). They have the property of antagonizing the signaling of all natural variants of TGF? ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.Type: GrantFiled: October 30, 2013Date of Patent: July 11, 2017Assignee: Centro De Inmunologia MolecularInventors: Ángel de Jesús Corria Osorio, Kalet León Monzón, Tania Carmenate Portilla, Amaury Pupo Meriño, Saumel Pérez Rodríguez
-
Patent number: 9670285Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: December 15, 2015Date of Patent: June 6, 2017Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULARInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Publication number: 20160166667Abstract: The invention describes vaccine compositions combined in the same proportion with the extracellular domains of growth factor receptors Her1 and Her2 or fragments thereof and furthermore very small size proteoliposomes derived from proteins of the outer membrane of Neisseria meningitidis and GM3 ganglioside (VSSP-GM3), administered subcutaneously. The disclosed compositions, which induce the production of antibodies are used for the treatment of malignancies and offer advantages because they completely remove the tumor mass thus preventing tumor regression due to the emergence of resistant variants.Type: ApplicationFiled: August 1, 2014Publication date: June 16, 2016Applicant: CENTRO DE INMUNOLOGIA MOLECULARInventors: Belinda SÁNCHEZ RAMÍREZ, Arianna YGLESIAS RIVERA, Amelia GUTIÉRREZ PÉREZ, Narjara GONZÁLEZ SUÁREZ
-
Publication number: 20160024220Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis.Type: ApplicationFiled: April 14, 2014Publication date: January 28, 2016Applicant: CENTRO DE INMUNOLOGIA MOLECULARInventors: JOSE ENRIQUE MONTERO CASIMIRO, ANGEL RAIMUNDO CASACO PARADA, ZAIMA MAZZORA HERRERA, RUBY ALONSO RAMIREZ, ROLANDO PEREZ RODRIGUEZ
-
Publication number: 20150284441Abstract: The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGF? molecule whose primary sequence has a high homology with the sequence of human TGF?. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (T?RII and T?RIII). They have the property of antagonizing the signaling of all natural variants of TGF? ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.Type: ApplicationFiled: October 30, 2013Publication date: October 8, 2015Applicant: CENTRO DE INMUNOLOGIA MOLECULARInventors: Ángel de Jesús Corria Osorio, Kalet León Monzón, Tania Carmenate Portilla, Amaury Pupo Meriño, Saumel Pérez Rodríguez
-
Publication number: 20150093385Abstract: The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside.Type: ApplicationFiled: February 21, 2013Publication date: April 2, 2015Applicant: CENTRO DE INMUNOLOGIA MOLECULARInventors: Ernesto Moreno Frias, Gertrudis Rojas Dorantes, Ana Victoria Casadesus Pazos
-
Publication number: 20140314709Abstract: The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptidess and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.Type: ApplicationFiled: November 10, 2011Publication date: October 23, 2014Applicant: CENTRO DE INMUNOLOGIA MOLECULARInventors: Kalet León Monzón, Tania Carmenate Portilla, Saumel Pérez Rodríguez, Neris Michel Enamorado Escalona, Agustín Bienvenido Lage Dávila
-
Patent number: 8778879Abstract: The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on cancer patients. The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. In another embodiment, the present invention concerns a method for purification of the chemical conjugate which not only provides greater purity for the therapeutic composition, but surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans.Type: GrantFiled: June 26, 2008Date of Patent: July 15, 2014Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Gryssell María Rodríguez Martínez, Lisel Viña Rodríguez, Loany Calvo González, Ariadna Cuevas Fiallo, Ernesto Chico Véliz, Agustín Bienvenido Lage Dávila, Tania Crombet Ramos, Airama Albisa Novo, Gisela Maria González Marinello
-
Patent number: 8758753Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.Type: GrantFiled: March 19, 2009Date of Patent: June 24, 2014Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
-
Patent number: 8759486Abstract: The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.Type: GrantFiled: November 26, 2010Date of Patent: June 24, 2014Assignee: Centro de Inmunologia MolecularInventors: Kalet León Monzón, Tania Carmenate Portilla, Karina García Martínez, Augustín Bienvendo Lage Davila, Samuel Pérez Rodríguez, Diamile González Roche, Gabriel Márquez Perera
-
Publication number: 20140031529Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: ApplicationFiled: September 3, 2013Publication date: January 30, 2014Applicants: CENTRO DE INMUNOLOGIA MOLECULAR, BIOCON LIMITEDInventors: RAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, JOSE ENRIQUE MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ
-
Patent number: 8591917Abstract: Vaccine compositions in which gangliosides and the OMP of N. meningitidis were combined to form very small size proteoliposomes (VSSP) to be administered subcutaneously are described, these compositions do not require the use of any additional adjuvant. The described compositions allow the immunological treatments with gangliosides, particularly N-AcGM3/VSSP and N-GcGM3/VSSP, showing advantages due to the less aggressive reaction in the site of injection and can be used in a simpler way and better for the patients.Type: GrantFiled: February 27, 2004Date of Patent: November 26, 2013Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Luis Enrique Fernández Molina, Circe Mesa Pardillo
-
Patent number: 8563003Abstract: The present invention relates to methods of treatment useful in chronic diseases, by means of the rupture of tolerance to self-antigens and increasing autoimmune response against these antigens. More particularly, the present invention relates to methods useful in the treatment of tumors that are growth dependent on the Epidermal Growth Factor, including non-small cell lung carcinoma. In the present invention a therapeutic combination is revealed that includes the combination of a vaccine against self antigens with a monoclonal antibody against peripheral T cells or a chemotherapeutic drug able to induce a depletion of peripheral T cells.Type: GrantFiled: December 4, 2002Date of Patent: October 22, 2013Assignee: Centro de Inmunologia MolecularInventors: Jose Enrique Montero Casimiro, Rolando Perez Rodriguez, Agustin Bienvenido Lage Davila